New treatments for type 2 diabetes to decrease the risk of heart disease and prolong life
In this lecture, Professor Nauck will discuss his research pertaining to the type 2 diabetes research and treatments he has developed over the last 25 years. He recognised the potential of the hormone GLP-1 for treating patients with type 2 diabetes, and has been able to help millions of people world-wide with type 2 diabetes by reducing their risk of heart disease and other metabolic conditions.
Professor Nauck was the first researcher who recognised the potential of the hormone GLP-1 for treating patients with type 2 diabetes. The hormone was discovered by Professor Jens Juul Holst in 1987, and in 1993, Professor Nauck showed the potential of the new hormone for treating type 2 diabetes which led to the development of incretin-based treatment. Through collaborating with Carolyn Deacon and Professor Jens Juul Holst, the proteolytic degradation of GLP-1 with the DPP-4 enzyme was demonstrated for the first time in humans, which led to the development of DPP 4-inhibitors which are now used all over the world.
He is currently the Head of Clinical Research at the Diabetes Division, Medical Department I, St. Josef-Hospital (Ruhr-University Bochum) in Bochum, Germany. Read more about his research here
Where: Florey lecture theatre, Medical school north
When: Tuesday 21 March, 5:30pm- 6:30pm